抄録
One of the problems in the development of immunotherapy in the past was poor evaluation of anti-tumor immune responses. Consequently, it was difficult to improve the immunotherapy. Various human tumor antigens recognized by T cells have recently been identified using various methods, including cDNA expression cloning with tumor reactive T cells and antibodies, as well as various cDNA subtraction methods in combination with in vitro T cell induction. The identification of tumor antigenic peptides recognized by T cells allows us to monitor anti-tumor T cell response quantitatively and qualitatively during immunotherapy as well as to develop more efficient immunotherapy with a sufficient amount of antigens in more immunogenic forms.
本文言語 | English |
---|---|
ページ(範囲) | 441-448 |
ページ数 | 8 |
ジャーナル | Biotherapy |
巻 | 16 |
号 | 5 |
出版ステータス | Published - 2002 9月 1 |
ASJC Scopus subject areas
- 腫瘍学
- 癌研究